军事知识服务平台
入院时血清TK-1、Flt3L、sCD30水平与非霍奇金淋巴瘤临床病理特征的相关性及对短期预后的预测效果
Correlation of serum TK-1, Flt3L and sCD30 levels at admission with clinicopathological characteristics of non-Hodgkin lymphoma and their predictive values for short-term prognosis
摘要 目的:探讨非霍奇金淋巴瘤(NHL)患者入院时血清胸苷激酶1(TK-1)、FMS样酪氨酸激酶3配体(Flt3L)、可溶性CD30(sCD30)水平及其与不同临床病理特征的相关性,以及对NHL患者短期预后的预测效果。方法:前瞻性病例系列研究。选取濮阳市安阳地区医院2022年2月至2024年2月收治的65例NHL患者(NHL组)及同期65名健康体检者(健康对照组),比较两组入院时血清TK-1、Flt3L、sCD30水平。比较不同临床病理特征NHL患者入院时血清TK-1、Flt3L、sCD30水平,采用Spearman相关性检验分析二者的相关性。随访6个月,记录NHL患者短期预后情况,分为预后不良(复发、转移、病死)和预后良好(生存且未复发、未转移、病情无进一步恶化)组,比较不同预后组入院时血清各指标水平。采用多因素logistic偏回归模型分析入院时血清各指标对NHL患者短期预后的影响;以随访记录预后状态为金标准,采用受试者工作特征(ROC)曲线分析入院时血清TK-1、Flt3L、sCD30水平单独及联合检测判断患者短期预后的效能。结果:NHL组入院时血清TK-1[(2.26±0.57)pmol/L比(1.07±0.11)pmol/L]、Flt3L[(84±5)pg/ml比(61±8)pg/ml]、sCD30[(150±11)kU/L比(90±10)kU/L]水平均高于健康对照组,差异均有统计学意义(均 P<0.001)。Ⅲ~Ⅳ期患者入院时血清TK-1[(2.51±0.55)pmol/L比(2.05±0.45)pmol/L]、Flt3L[(88±4)pg/ml比(81±5)pg/ml]、sCD30[(154±12)kU/L比(145±10)kU/L]水平均高于Ⅰ~Ⅱ期患者,低分化患者入院时血清TK-1[(2.42±0.62)pmol/L比(2.12±0.41)pmol/L]、Flt3L[(86±5)pg/ml比(83±5)pg/ml]、sCD30[(157±11)kU/L比(144± 11)kU/L]水平均高于中高分化患者,差异均有统计学意义(均 P<0.05)。入院时血清TK-1( r=0.60)、Flt3L( r=0.63)、sCD30( r=0.62)水平与病理分期均呈正相关,TK-1( r=-0.61)、Flt3L( r=-0.60)、sCD30 ( r=-0.63)水平与分化程度均呈负相关,差异均有统计学意义(均 P<0.001)。随访6个月内预后不良14例(21.5%),预后良好51例(78.5%)。预后不良组患者入院时血清TK-1[(2.53±0.60)pmol/L比(2.19±0.53)pmol/L]、Flt3L[(90±4)pg/ml比(83±6)pg/ml]、sCD30[(158±10)kU/L比(147±10)kU/L]水平均高于预后良好组,差异均有统计学意义(均 P<0.05)。多因素logistic偏回归分析结果显示,入院时血清TK-1( OR=1.82,95% CI:1.17~4.05, P<0.001)、Flt3L( OR=1.89,95% CI:1.14~3.12, P<0.001)、sCD30( OR=1.95,95% CI:1.03~3.70, P<0.001)升高为NHL患者发生短期预后不良的独立危险因素。ROC曲线分析显示,入院时血清TK-1、Flt3L、sCD30单独预测NHL患者发生短期预后不良的曲线下面积(AUC)值分别为0.747、0.734、0.727,三者联合预测的AUC为0.926,最佳临界值时的灵敏度和特异度分别为85.71%、88.24%。 结论:NHL患者入院时血清TK-1、Flt3L、sCD30水平均较健康人高,三者水平与NHL患者病理分期和分化程度相关,预后不佳患者三者水平均升高,且三者联合检测对NHL患者短期预后具有较好的预测价值。
Abstract:
Objective:To investigate the levels of serum thymidine kinase 1 (TK-1), FMS-like tyrosine kinase 3 ligand (Flt3L) and soluble CD30 (sCD30) at admission in patients with non-Hodgkin lymphoma (NHL), their correlations with various clinicopathological characteristics, and their predictive values for short-term prognosis.Methods:A prospective case series study was conducted. Sixty-five NHL patients who were admitted to Anyang District Hospital in Puyang City from February 2022 to February 2024 (NHL group) and 65 healthy individuals undergoing routine health examinations during the same period (healthy control group) were enrolled, and the serum levels of TK-1, Flt3L and sCD30 at admission were compared between the two groups. Serum levels of TK-1, Flt3L and sCD30 at admission were compared among NHL patients with varying clinicopathological characteristics, and Spearman correlation analysis was used to evaluate the relationships between these markers and clinicopathological characteristics. Patients were followed up for 6 months, the short-term prognosis was recorded and categorized as poor prognosis (relapse, metastasis or death) or good prognosis (survival without relapse or metastasis, and no further disease progression),and the serum levels of each marker at admission were compared between the two groups. Multivariate logistic regression models were employed to analyze the impact of serum levels of these markers at admission on short-term prognosis. Using follow-up records of prognosis status as the gold standard, receiver operating characteristic (ROC) curves were plotted to analyze the efficacy of individual and combined detection of serum TK-1, Flt3L and sCD30 at admission for predicting the short-term prognosis of patients.Results:At admission, the serum levels of TK-1 [(2.26±0.57) pmol/L vs. (1.07±0.11) pmol/L], Flt3L [(84±5) pg/ml vs. (61±8) pg/ml] and sCD30 [(150±11) kU/L vs. (90±10) kU/L] in the NHL group were higher than those in the healthy control group, and the differences were statistical significant (all P < 0.001). Among NHL patients, the serum levels of TK-1 [(2.51±0.55) pmol/L vs. (2.05±0.45) pmol/L], Flt3L [(88±4) pg/ml vs. (81±5) pg/ml] and sCD30 [(154±12) kU/L vs. (145±10) kU/L] in patients with stage Ⅲ-Ⅳ were higher than those in patients with stage Ⅰ-Ⅱ, and the serum levels of TK-1 [(2.42±0.62) pmol/L vs. (2.12±0.41) pmol/L], Flt3L [(86±5) pg/ml vs. (83±5) pg/ml] and sCD30 [(157±11) kU/L vs. (144±11) kU/L] in patients with poorly differentiation were higher than those in patients with intermediate or high differentiation, and the differences were statistically significant (all P < 0.05). At admission, serum levels of TK-1 ( r = 0.60), Flt3L ( r = 0.63) and sCD30 ( r = 0.62) were positively correlated with pathological stage, whereas the levels of TK-1 ( r = -0.61), Flt3L ( r = -0.60) and sCD30 ( r = -0.63) were negatively correlated with the degree of differentiation, and the differences were statistical significance (all P < 0.001). During a 6-month follow-up, 14 patients (21.5%) had poor prognosis, while 51 patients (78.5%) had good prognosis. At admission, the serum levels of TK-1 [(2.53±0.60) pmol/L vs. (2.19±0.53) pmol/L], Flt3L [(90±4) pg/ml vs. (83±6) pg/ml] and sCD30 [(158±10) kU/L vs. (147±10) kU/L] in the poor prognosis group were higher than those in the good prognosis group, and the differences were statistically significant (all P < 0.05). Multivariate logistic partial regression analysis revealed that elevated serum levels of TK-1 ( OR = 1.82, 95% CI: 1.17-4.05, P < 0.001), Flt3L ( OR = 1.89, 95% CI: 1.14-3.12, P < 0.001) and sCD30 ( OR = 1.95, 95% CI: 1.03-3.70, P < 0.001) at admission were independent risk factors for short-term poor prognosis in patients with NHL. ROC curve analysis indicated that, when assessed individually, the areas under the curve (AUC) for predicting short-term poor prognosis in NHL patients were 0.747 for TK-1, 0.734 for Flt3L, and 0.727 for sCD30. The combined predictive value of all three markers yielded an AUC of 0.926, with a sensitivity of 85.71% and a specificity of 88.24% at the optimal cutoff point. Conclusions:At admission, serum levels of TK-1, Flt3L and sCD30 are elevated in patients with NHL compared with healthy individuals; these biomarker levels correlate with disease stage and tumor differentiation, and are further increased in patients with poor prognosis. Moreover, the combined detection of these three markers demonstrates good predictive accuracy for short-term prognosis in NHL patients.